Investment - Invest in biotech

Australia Biotech Invest 2016 provided a platform for 24 innovative life science companies to present their business to more than 150 investors.

Australia Biotech Invest was held from 26-27 October in Melbourne, part of the International BioFest and the largest-ever gathering in the Australian life sciences.

View the company profiles below or read the event handbook.

AdAlta Limited

AdAlta Limited (ASX:1AD) is an Australian-based drug discovery and development company with a global focus. AdAlta is developing its current lead i-body candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other fibrotic diseases. There are few therapies available to effectively treat fibrosis and a high-unmet medical need globally. AdAlta is focused on commercialising its proprietary i-body technology platform to generate a new class of protein therapeutics with multiple applications to treat a wide range of human diseases.


Adherium (ASX:ADR) is a global leader in digital health technologies which address sub-optimal medication use in chronic diseases. Adherium has the broadest range of "smart" devices for respiratory medications globally. Using the Smartinhaler™ solution enables patients and healthcare professionals to track medication adherence, set daily reminders, and discover insights into their medication usage. The Smartinhaler™ platform has been used in over 30 countries, in more than 65 projects (clinical, device validation or other) and has peer reviewed journal articles resulting from 14 studies.


Formed in 2014 AusCann believes that patients have the right to high-quality, economical, and clinically-validated cannabis medicines. The company has a strong Board with complementary skill-sets, experience and networks. It has partnered with global leaders, including the largest medicinal cannabis producer in North America Canopy Growth Corp, and Spanish plant breeders Phytoplant Research and the State Agricultural Biotechnology Centre at Murdoch University, to ensure access to expertise and relevant IP for plant breeding, cultivation and production, and clinical studies.


Bionomics is a clinical stage biopharmaceutical company leveraging its proprietary technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics’ lead drug candidate BNC210, currently in Phase II for the treatment of generalised anxiety disorder and for PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine receptor. The company is also developing BNC101, its lead humanised monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer. Bionomics has strategic partnerships with Merck & Co., Inc. in pain and cognition.

Biotron Limited

Biotron Limited (ASX:BIT) is developing novel drugs targeting serious virus diseases. The company’s core expertise lies in developing drugs targeting a class of viral proteins found in a broad range of viruses. These proteins (viroporins) are ideal drug targets as they are essential for virus infectivity and pathogenicity.

Elk OrthoBiologics

Elk OrthoBiologics (“Elk”) is an Australian public unlisted biotechnology company. Elk is developing a minimally invasive gene therapy for stabilising prosthetic hip and knee implants that fail due to “aseptic loosening”. This debilitating condition results from chronic inflammatory responses to microscopic particles generated by the prosthesis and is the most common cause for prosthesis failure. Over 3 million hip and knee implant procedures occur globally (CAGR >6%). There is a growing and significant unmet medical need. Elk is preparing for a European Phase IIa clinical trial in 2017. Elk is finalising plans for an upcoming ASX listing in order to fully fund the Phase IIa clinical program.

EpixAxis Therapeutics

EpiAxis Therapeutics is a Canberra based immuno-oncology company, which is pursuing a discovery and translational program directed at the prevention of metastatic disease by prolonging remission. The program is focused on the pivotal epigenetic enzyme system controlling the proliferation of circulating tumour cells (CTC) and cancer stem cells (CSC). The enzyme target is the nuclear bound lysine-specific demethylase 1 (LSD1) & its upstream regulator, the theta isoform of protein kinase C (PKCθ). EpiAxis is positioning itself to become the leading cancer recurrence prevention company with its proprietary LSD1 & PKCθ inhibitors included in the standard of care (SoC) for cancer.

GI Therapies

GI Therapies is a Melbourne based private company developing an innovative late-stage medical product designed to address a range of chronic GI motility disorders. Lead indication is treating chronic idiopathic constipation (CIC) in adults and children – an important market with a big unmet need. European marketing approval is anticipated Q4 2016 with Australian approval in early 2017 while the company is poised to initiate clinical trials for US pre-marketing approval by FDA.

Health Delivered

Health Delivered designs dietary management technology solutions to tackle the growing rates of obesity, diabetes and other chronic health issues. The goal is to optimise patient care by providing health care professionals with tools to improve their efficiency and optimise client engagement.
Through the platform, medical professionals will have access to real-time data regarding the dietary and biometric inputs of their patients. This will allow them to assess existing treatments and recommendations, and engage with their clients remotely with personalised data in between regular consultations.

IDT Australia

IDT Australia (ASX:IDT) is commercialising a portfolio of 24 generic drugs to manufacture and sell via US distribution partners, as well as exploring EU and Japanese sales opportunities. With IDT’s 2013 Temozolomide ANDA filing and subsequent FDA approval in 2016 this signifies IDT’s move to rapidly become a specialty generics business with near term revenue build up.

IDT has extensive experience in the development and production of high potency and high containment pharmaceutical products to FDA, TGA and EMEA standards. IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.

LBT Innovations

LBT Innovations is a medical technology company that develops the latest intelligent imaging technology and interpretative software to improve the efficiency and quality of clinical diagnosis across a wide spectrum of healthcare applications. This benefits patients who can receive quicker and more reliable treatment so they can get back to full health faster. We do this by combining our in-depth knowledge of clinical practice and healthcare delivery with complex engineering and software development to produce simple-to-use products that greatly increase clinical efficiency and drive down costs.


Novogen is an oncology-focused biotechnology company, headquartered in Sydney, Australia. The company aims to create sustainable, long-term shareholder value by providing meaningful new therapies for patients with high unmet medical need.

Omni Innovation

Omni Innovation is a privately held Australian biotechnology company delivering clinically validated foods for Special Medical Purposes (Medical Foods) and Functional Nutrition to improve the lives of people with chronic and lifestyle- related diseases. The company focuses on scientifically validated, IP protected medical nutrition that has applications in large healthcare markets with significant unmet needs in first-world and emerging markets including the EU, US, China, SE Asia, India and the Middle East.

Opal Biosciences

With the rise in antibiotic resistance and few new ones in development, novel effective treatment for infections have the potential to be life-saving. Opal Biosciences Limited (“Opal”) is an innovative player in infectious disease treatment, committed to tackling this serious global health threat. Opal targets treatment of human infection: a high growth, commercially attractive market segment. Opal is progressing the development of its preclinical stage anti-infective candidate which has shown activity in vitro against serious human pathogens including, Staph aureus (Golden Staph), Neisseria gonorrhoea and Mycobacterium tuberculosis (TB).


Orthocell is a regenerative medicine company focused on restoring the function and mobility of patients by developing innovative products to repair a variety of bone, tendon, cartilage and other soft tissue injuries and defects.

Paranta Biosceinces

Paranta Biosciences is a clinical stage Australian biopharmaceutical company developing potentially transformative therapies based on PB01 (a form of recombinant human follistatin) that target indications of high unmet need with significant market potential. The company is progressing two major development programs: inhaled PB01 for respiratory indications and intravenous PB01 for oncology indications.

Petri Exchange

Petri Exchange is an Australian is a biotechnology corporate advisory specialist founded in 2016. Combining expertise in biotech, finance and accounting Petri Exchange’s vision is to connect both private and public investors with late stage commercialised medical research opportunities via their online exchange. We connect investors with commercial opportunities from the best medical research and support both the researcher and investor to navigate the complexities of research commercialisation. Petri Exchange ensures medical research commercialisation opportunities are investor-ready, and provides supporting services throughout the investment lifecycle. Current project partners include some of Australia’s leading research institutes and cover a wide range of therapeutic areas. We are looking to work with investors who are interested in leading early stage biotechnology investments, as well as researchers who are looking to take advantage of the new suite of private sector commercialisation incentives.


Phosphagenics is an Australian biotechnology company that is developing and commercialising innovative human health, animal health and personal care products using its proprietary TPM® delivery system. TPM® is derived from Vitamin E and is proven to enhance the solubility and oral, dermal and transdermal absorption of various pharmaceuticals and nutrients. Phosphagenics’ has several successfully commercialised TPM®-enhanced products, an exciting pipeline of TPM®- enhanced patches, gels and injectable products for human health, and TPM® products to enhance feed efficiency and health of livestock. Phosphagenics is listed on the ASX (POH) and through ADRs in the US (PPGNY).

Proteomics International

Proteomics International Laboratories Ltd (PILL) applies its disruptive technology platform to study the structure and function of proteins, focusing on the discovery of new diagnostic biomarkers. PILL has developed a unique predictive test for diabetic kidney disease, known as PromarkerD, and has recently signed its first million-dollar licensing deal for its commercialisation. PILL operates in three integrated areas unified by its proprietary proteomics-based technology platform: Diagnostics, Peptide drug discovery and Analytical services (specialising in biosimilars). This sustainable business model merges blue sky opportunities with cash flow, using revenue generated from analytical services to fund pioneering research into next-generation diagnostic tests and drug discovery.

Race Oncology

Race Oncology is a specialty pharma company pursuing later stage drug assets that have been overlooked by big pharma. Our first asset is a cancer chemotherapy drug called Bisantrene, which was the subject of more than 40 Phase II studies before it was lost in a series of big pharma mergers during the 1990s. We intend to launch Bisantrene during calendar 2017 via a named patient program (NPP) in Europe, aimed at relapsed/refractory Acute Myeloid Leukemia (AML). We are now seeking licensing partners for all countries outside Europe.


Regeneus Ltd (ASX: RGS) is an ASX-listed clinical-stage regenerative medicine company using stem cell and immunotherapy technologies to develop a portfolio of innovative cellular therapies targeting areas of significant unmet medical needs in both human and animal health markets with a focus on osteoarthritis (OA) and other musculoskeletal disorders, oncology and dermatology disease.

Reproductive Health Science

Reproductive Health Science Ltd (ASX:RHS) is a developer of advanced single cell genomic technologies to improve health and research outcomes. Based in Adelaide, South Australia, RHS manufactures products and provides services for the analysis of the genetic contents of limited DNA samples. The company’s products are sold globally through a network of 8 distributors and via direct sales.


SkinView is a subsidiary of GP2U Telehealth, Australia’s leading provider of online care and telehealth. SkinView has developed a suite of very low cost attachments for smartphones capable of turning them into connected medical devices. SkinView is also developing complementary algorithms to facilitate automated diagnosis of target disease states, including melanoma. SkinView will initially focus on eliminating unnecessary deaths from melanoma by lowering the barriers to dermoscopy utilisation and through the automated diagnosis of suspicious skin lesions.

Vectus Biosystems

Vectus Biosystems Limited is a drug discovery company that has developed a library of more than 1,000 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties. Fibrotic disease contributes to more than 40 per cent of deaths worldwide, a figure that includes deaths caused by atherosclerosis, the biggest killer in the developed world, as well as diseases affecting the lung, liver and kidney, among others. Treatments for fibrotic diseases represent a major unmet clinical need, and where drugs exist, the only slow the progression of disease. In contrast, Vectus’ compounds have been shown to reverse fibrosis in preclinical models.